An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis

Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy. Methods & clinical development 2018-06, Vol.9, p.270-277
Main Authors: Heider, Robin M, Smestad, John A, Lemus, Hernan Nicolas, Wilbanks, Brandon, Warrington, Arthur E, Peters, Justin P, Rodriguez, Moses, Maher, 3rd, L James
Format: Article
Language:English
Subjects:
Aptamers
Bacterial proteins
Deoxyribonucleic acid
Design
DNA
Encephalomyelitis
Multiple sclerosis
Myelin
Myelination
Streptavidin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus. Here, we report an assay of myelin binding with results that correlate with remyelination outcome , as shown for data from a set of DNA aptamer complexes of different size and formulation. This assay will be valuable for future screening of MS regenerative therapies targeting remyelination.
ISSN:2329-0501
2329-0501
DOI:10.1016/j.omtm.2018.03.005